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The relative contributions of the JNK subtypes in inflammatory 𝛽-cell failure and apoptosis are unclear. The JNK protein family
consists of JNK1, JNK2, and JNK3 subtypes, encompassing many different isoforms. INS-1 cells express JNK1𝛼1, JNK1𝛼2, JNK1𝛽1,
JNK1𝛽2, JNK2𝛼1, JNK2𝛼2, JNK3𝛼1, and JNK3𝛼2 mRNA isoform transcripts translating into 46 and 54 kDa isoform JNK proteins.
Utilizing Lentiviral mediated expression of shRNAs against JNK1, JNK2, or JNK3 in insulin-producing INS-1 cells, we investigated
the role of individual JNK subtypes in IL-1𝛽-induced 𝛽-cell apoptosis. JNK1 knockdown prevented IL-1𝛽-induced INS-1 cell
apoptosis associated with decreased 46 kDa isoform JNK protein phosphorylation and attenuated Myc expression. Transient
knockdown of Myc also prevented IL-1𝛽-induced apoptosis as well as caspase 3 cleavage. JNK2 shRNA potentiated IL-1𝛽-induced
apoptosis and caspase 3 cleavage, whereas JNK3 shRNA did not affect IL-1𝛽-induced 𝛽-cell death compared to nonsense shRNA
expressing INS-1 cells. In conclusion, JNK1 mediates INS-1 cell death associated with increased Myc expression. These findings
underline the importance of differentiated targeting of JNK subtypes in the development of inflammatory 𝛽-cell failure and
destruction.
1. Introduction
Inflammatory𝛽-cell inhibition and apoptosis are increasingly
accepted as key contributors to failing insulin secretion lead-
ing to type 1 and type 2 diabetes [1, 2]. Interleukin-1, a 17 kDa
proinflammatory cytokine and mediator of inflammation,
fever, and acute-phase responses [1, 3], inhibits 𝛽-cell func-
tion in vitro and in vivo by signaling via NF𝜅B and mitogen
activated protein kinases (MAPK) to activate endoplasmic
reticulum and mitochondrial death pathways [4–7]. The
MAPK family encompasses the extracellular signal-regulated
kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 cas-
cades. The precise contribution of the JNK pathway to stress-
induced 𝛽-cell failure is not fully understood, especially with
regard to the differential roles of the JNK subtypes, JNK1,
JNK2, and JNK3.
The JNK proteins control the expression of immediate
early genes such as AP-1 transcription factor family members
and are important regulators of both apoptosis and survival,
depending on the biological context [8, 9].Threemammalian
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genes encoding for JNK have been identified: jnk1, jnk2, and
jnk3, located on different chromosomes [10, 11]. JNK1 and
JNK2 are expressed in a large variety of tissues regulating cell
proliferation, differentiation, inflammation, autoimmunity,
obesity, and tumorigenesis [12]. JNK3 expressionwas thought
to be restricted to the brain, heart, and testes [13, 14]; however,
more recently, JNK3was found to be expressed also in human
and mouse pancreatic 𝛽-cells [15]. All three JNK subtypes
control cellular apoptosis. Mice deficient in a single JNK
allele survive, as do jnk1−/−jnk3−/− and jnk2−/−jnk3−/− mice,
whereas combined genetic disruption of jnk1 and jnk2 alleles
causes early embryonic death due to severe dysregulation
of apoptosis in the brain [14]. Additionally, jnk1−/−/jnk2−/−
mouse embryonic fibroblasts (MEFs) are protected against
UV-induced apoptosis, indicating that JNK1 and JNK2 are
required for a normal apoptotic response to UV exposure
[16]. Furthermore, jnk3−/− mice are protected from stroke,
neuronal death, and oxidative stress [17]. Supporting these
direct observations of the importance of JNK in proapoptotic
signalling, cell-permeable JNK inhibitory protein-1 (JIP-1)
derived JNK inhibitory peptides or the JNK inhibitory small
molecule SP600125 decrease intracellular JNK signalling and
improve cell survival in vitro and in vivo [18–22].
Splicing of the jnk genes gives rise to more than twelve
different transcript variants [13, 23] translating into proteins
with and without a COOH-terminal extension to generate
both 46 kDa and 54 kDa isoform proteins with a high level
of homology [24]. Initially, the different JNK subtypes were
thought to have largely redundant functions, but different
tissue distribution, substrate preferences, and expression pat-
terns support that the JNK subtypes also have nonredundant
functions and are involved in distinct cellular processes
[10, 12, 13, 23, 25]. However, little is known about how the
individual JNK isoforms and subtypes mediate apoptosis.
Apart from phosphorylating and activating members of the
activating protein-1 (AP-1) transcription factor family, JNK
proteins regulate other proteins involved in cell proliferation
and apoptosis, including p53, Myc, and members of the Bcl-2
family of proteins [6, 26, 27].
The precise contribution of the individual JNK sub-
types in mediating IL-1𝛽-induced 𝛽-cell apoptosis is largely
unknown, although a protective role of JNK3 in IL-1𝛽, TNF-
𝛼, and IFN-𝛾-induced 𝛽-cell apoptosis via Akt2 signaling has
been suggested [15, 28]. In these studies, no differentiation
was made between the roles of the JNK subtypes in the sig-
naling pathways of the three individual proinflammatory
cytokines. Since JNK subtype activation is stimulus depen-
dent and as IL-1𝛽 is indispensable in the proapoptotic com-
bination of inflammatory cytokines, the action of TNF-𝛼 and
INF-𝛾 being mainly to synergize with IL-1𝛽, it is important
to investigate the differential role of the JNK subtypes in
stimulus-specific pancreatic 𝛽-cell signalling.
Here, we investigated the individual roles of JNK1, JNK2,
and JNK3 in IL-1𝛽-induced apoptosis in insulin-producing
INS-1 cells and provide evidence for a critical role of JNK1 in
mediating IL-1𝛽-induced 𝛽-cell apoptosis, whereas JNK2 but
not JNK3 conferred protection.
2. Materials and Methods
2.1. Cell Culture and Reagents. The clonal rat 𝛽-cell line INS-1
[29] (gift fromWollheim,Geneva, Switzerland) and INS-1 cell
lines stably expressing shRNA [30]were grown inRPMI-1640
medium with 11mmol/L glucose (Invitrogen, Naerum, Den-
mark) supplemented with 50𝜇mol/L 𝛽-mercaptoethanol,
100U/mL penicillin, 100𝜇g/mL streptomycin, and 10% heat-
inactivated fetal bovine serum (FBS) (Invitrogen). Cells
were incubated in a humidified atmosphere of 5% CO
2
at
37∘C. Recombinant mouse IL-1𝛽 was from BD Bioscience
Pharmingen (San Diego, CA, USA).
JNK1(F-3) mouse monoclonal antibody raised against
amino acid 1-384 of full length JNK1 p46 human origin was
purchased from Santa Cruz Technologies (Santa Cruz, CA,
USA, catalog number: sc-1648, used at 1 : 1000 dilution). JNK2
rabbit polyclonal antibody raised against a synthetic peptide
for human JNK2 (catalog number: #4672, used at 1 : 1000
dilution), JNK3 rabbit monoclonal antibody raised against a
synthetic peptide for human JNK3 (catalog number: #55A8,
used at 1 : 1000 dilution), P-JNK (Thr183/Tyr185) polyclonal
rabbit antibody raised against a synthetic phosphopeptide
corresponding to residues surrounding Thr183/Tyr185 of
human SAPK/JNK (catalog number: #9251, used at 1 : 1000
dilution), T-JNK polyclonal rabbit antibody raised against a
recombinant human JNK2 fusion protein (catalog number:
#9252, used at 1 : 1000 dilution), cleaved caspase 3 (Asp175)
rabbit polyclonal antibody raised against amino terminal
residues adjacent to Asp175 in human caspase 3 (catalog
number: #9661, used at 1 : 500 dilution), Myc (D84C12)
rabbit monoclonal antibody raised against synthetic peptide
corresponding to amino-terminal residues of c-Myc (catalog
number: #5605, used at 1 : 1000 dilution), and 𝛽-tubulin (9F3)
rabbit monoclonal antibody raised against human 𝛽-tubulin
(catalog number: #2128, used at 1 : 1000 dilution) were all
from Cell Signalling (Beverly, MA, USA). The mouse mon-
oclonal 𝛽-actin antibody raised against 𝛽-cytoplasmic actin
N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-
Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to Keyhole Limpet
Haemocyanin (KLH)was obtained fromAbcam (Cambridge,
UK, catalog number: ab6276, used at 1 : 10000 dilution). The
specificity of the JNK antibodies was previously verified
against recombinant JNK1, JNK2, and JNK3 protein using
Western blot analysis [30].
HEK293FT cells, used to produce Lentivirus, were cul-
tured in D-MEM medium (Invitrogen) supplemented with
100U/mL penicillin, 10 nM MEM nonessential amino acids,
1mM sodium pyruvate, and 10% FBS (Invitrogen) (complete
D-MEM).
HT1080 cells, used for virus titration, were cultured in
D-MEMmedium (Invitrogen) supplemented with 100U/mL
penicillin, 100 𝜇g/mL streptomycin, and 10% FBS (Invitro-
gen).
2.1.1. Lentivirus Expressing shRNA and INS-1 Stable Cell
Line Production. INS-1 cell lines, stably expressing JNK1,
JNK2, or JNK3 shRNAs, nonsense shRNA, or empty vector,
were created as described in [31]. In brief, INS-1 cells
were transduced with an MOI of 5 with virus generated
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by transfection of HEK293FT cells with the Lentiviral
vectors pLKO.1 JNK1 (TRCN0000055115), pLKO.1 JNK2
(TRCN0000012590), pLKO.1 JNK3 (TRCN0000012634), or
empty vector (all from Open Biosystems, Thermo Scientific,
St. Leon-Rot, Germany) or pLKO.1 nonsense (SHC002)
(Sigma, Brondby, Denmark). All constructs contained a
puromycin-resistance gene as mammalian selection marker,
and stably transduced INS-1 cells were selected using 1𝜇g/mL
puromycin (Sigma). INS-1 cell lines were passaged a mini-
mum of three times and tested for knockdown efficiency and
specificity compared to empty vector and nonsense shRNA
expressing INS-1 cell lines.
2.2.Microarray Analysis. Total RNAwas isolated using Trizol
(Sigma) followed by RNeasy Mini Elute Kit (Qiagen, Hilden,
Germany) purification. 1 𝜇g of total RNA was used to pre-
pare targets by One-Cycle Target labeling kit (Affymetrix,
Santa Clara, CA, USA) following the instructions of the
manufacturer. Hybridization cocktails were hybridized onto
Rat Genome 230 2.0 GeneChips, containing 31,099 rat gene
probes, at 45∘C for 17 h (60 Rpm) in a Hybridization Oven
640 (Affymetrix). GeneChips were rinsed and stained in
a GeneChip fluidics station 450 using the fluidics protocol
“EukGE-WS2v5 450” (Affymetrix). Chips were scanned in
a GeneChip scanner 3000 (Affymetrix). For all conditions,
three separate experiments were analyzed on separate arrays;
that is, a total of 36 arrays were used. Array data is available
at Arrayexpress [31] (https://www.ebi.ac.uk/arrayexpress),
accession number E-MTAB-3146.
2.2.1. Microarray Data Preprocessing and Visualization. To
adjust for nonspecific hybridization, optical effects, and
comparability, probe intensities were combined and nor-
malized using the RMA method. All intensities were log
2
-
transformed. Significant differential expression was assessed
using the moderated 𝑡-statistics for pairwise comparison
between conditions implemented in the LIMMA package.
The comparisons performedwere 45min IL-1𝛽 exposed JNK1
knockdown (KD) INS-1 cells adjusted for nonexposed JNK1
KD versus 45min IL-1𝛽 exposed NS control INS-1 cells
adjusted for nonexposed NS control INS-1 cells; 45min IL-
1𝛽 exposed JNK2 KD INS-1 cells adjusted for nonexposed
JNK2 KD versus 45min IL-1𝛽 exposed NS control INS-1 cells
adjusted for nonexposed NS control INS-1 cells; and 45min
IL-1𝛽 exposed JNK3 KD INS-1 cells adjusted for nonexposed
JNK3 KD versus 45min IL-1𝛽 exposed NS control INS-1
cells adjusted for nonexposed NS control INS-1 cells. Genes
were considered to be significantly regulated if the log
2
fold
change was >1 or < −1 and the 𝑃 value was <0.05. Only
probes that could be mapped to gene identifiers using the
“rat2302.db” probe annotation package were considered for
further analysis.
For clustering analysis, we used hierarchical clustering
as implemented in the heatmap.2 function in the gplots r
package. Briefly, the mean log
2
expression value for three
replicates of the 12 conditions was calculated for each probe.
Overrepresented biological processes among groups of reg-
ulated genes were identified by hypergeometric testing of
gene ontology (GO) terms using DAVID [32, 33]. Only GO
terms reaching a Benjamini corrected 𝑃 value <0.05 were
considered significantly overrepresented.
2.3. cDNA and qRT-PCR. INS-1 cells were exposed to 150 pg/
mL IL-1𝛽 or vehicle over either a 12 h (stable shRNA cell
line experiments) or 24 h (INS-1 cell line experiments) time
course and total RNA was isolated using the RNeasy kit
(Qiagen) and quantified on a NanoDrop 1000 microvolume
spectrophotometer. The RNA was treated with recombinant
shrimp DNase (Affymetrix), and first strand cDNA was syn-
thesized from 2 𝜇g of RNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Carlsbad,
CA, USA) following the manufacturer’s protocol. Quantita-
tive RT-PCR was performed in a 10 𝜇L volume using 0.5 𝜇L
of premixed Taqman primer/probes (Applied Biosystems),
5 𝜇L 2x Taqman Universal Master Mix (Applied Biosystems),
and 4.5 𝜇L template (20 ng) and run on a 384-well plate in
triplicate on the Applied Biosystems Prism 7900HT real-
time PCR machine for 40 cycles. The results were analyzed
using SDS 2.4 software (Applied Biosystems). The following
primer/probes were purchased from Applied Biosystems:
Hprt1 (Rn01527840 m1), RN18S1 (Hs03928990 g1), JNK1
(Rn01453358 m1), JNK2 (Rn00569058 m1), JNK3 (Rn00563035
m1), Jun (Rn00572991 s1), Trp53 (Rn00755717 m1),
Junb (Rn00572994 s1), Jund (Rn00824678 s1), and Myc
(Rn00561507 m1). The primer/probe sequences for the JNK
isoforms are listed in Table 1 and synthesized by Integrated
DNA Technologies (IDT, Berchem, Belgium). We utilized
the human isoform-specific primer and probe sequences
determined by Dreskin et al. [34] and modifying them
based upon a cross species homology comparison between
human and mouse, as the rat JNK isoform sequences
were not published. Relative transcript quantities were cal-
culated by the standard curve method and normalized to
the average of the housekeeping genes 18S and Hprt1. The
appropriate housekeeping genes were selected by analyzing
the mRNA expression of four common housekeeping genes,
GAPDH, PPIA, 18S, and Hprt1, in INS-1 cells after 12 and
24 h exposures to IL-1𝛽. The two genes used were the least
variable following IL-1𝛽 treatment.
2.4. Transfection Studies. INS-1 cells (0.8 × 106 cells/well for
Western blotting and 0.075 × 106 cells/well for Cell Death
Detection Assay) were transfected with siRNA directed
against rat Myc (Sigma), negative control siRNA (mission
siRNAuniversal negative control, Sigma), or vehicle.The cells
were transfected using DharmaFECT4 (Thermo Scientific,
Denmark) according to the manufacturer’s protocol, with a
final concentration of siRNA of 50 nmol/L. The cells were
incubated for 22 h with siRNA or vehicle and then exposed
to IL-1𝛽 (150 pg/mL) or left nonexposed for 24 h. Protein was
isolated and analyzed by Western blotting and apoptotic cell
death was measured by the Cell Death Detection ELISAPLUS
(Roche, Hvidovre, Denmark).
2.5. Western Blot Analysis. INS-1 cells or INS-1 cell lines
stably expressing shRNA were grown to 80–90% confluence,
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Table 1: Rat JNK isoform-specific primers.
Isoform Sense primer (5󸀠-3󸀠) Antisense primer (5󸀠-3󸀠) Probe
JNK1𝛼1 GAGAAATGGTTTGCCACA ACTGCTGCACCTGTGCTA (VIC)-TTGAACAGCTCGGAACACCTTGTCCTG-(TAMRA)
JNK1𝛼2 GAGAAATGGTTTGCCACA ACTGCTGCACCTAAAGGA (VIC)-TTGAACAGCTCGGAACACCTTGTCCTG-(TAMRA)
JNK1𝛽1 GGAGAAATGATCAAAGGTG ACTGCTGCACCTGTGCTA (VIC)-TTGAACAGCTCGGAACACCTTGTCCTG-(TAMRA)
JNK1𝛽2 GGAGAAATGATCAAAGGTG ACTGCTGCACCTAAAGGA (VIC)-TTGAACAGCTCGGAACACCTTGTCCTG-(TAMRA)
JNK2𝛼1 GAGAGCTGGTGAAAGGTT TTACTGCTGCATCTGTGC (VIC)-AAAGTTATTGAACAGCTAGGAACACCATCC-(TAMRA)
JNK2𝛼2 GAGAGCTGGTGAAAGGTT ACTGCTGCATCTGAAGGC (VIC)-AAAGTTATTGAACAGCTAGGAACACCATCC-(TAMRA)
JNK2𝛽1 GAAATGGTCCTCCATAAAG TTACTGCTGCATCTGTGC (VIC)-AAAGTTATTGAACAGCTAGGAACACCATCC-(TAMRA)
JNK2𝛽2 GAAATGGTCCTCCATAAAG ACTGCTGCATCTGAAGGC (VIC)-AAAGTTATTGAACAGCTAGGAACACCATCC-(TAMRA)
JNK3𝛼1 GCCCTCACCTTCAGCACAG AGGCAGGCGGCTAGTCAC (VIC)-AGCAGTGAGAGTCTCCCTCCATCCTCGT-(TAMRA)
JNK3𝛼2 GCCCTCACCTTCAGGTG AGGCAGGCGGCTAGTCAC (VIC)-AGCAGTGAGAGTCTCCCTCCATCCTCGT-(TAMRA)
exposed to IL-1𝛽 (150 pg/mL) or vehicle for up to 24 h,
washed in ice-cold PBS, and lysed for 15min on ice using 1x
lysis buffer (Cell Signaling). The protein concentration was
measured by the Bradford method (Bio-Rad, Copenhagen,
Denmark). 30–40 micrograms of total protein were mixed
with 4x LDS sample buffer (Invitrogen), heated for 5min at
70∘C, and loaded on 10% NuPAGEBis-Tris gel (Invitrogen).
Proteins were blotted onto nitrocellulose filter membranes
(Invitrogen). Ponceau staining measuring total protein was
used as loading control. The blots were blocked for 1 h in 1x
tris-buffered saline (pH7.6) containing 0.1%Tween 20 and 5%
BSA and afterwards incubated overnight at 4∘Cwith primary
antibody. Blots were rinsed and incubated with a rabbit
secondary horseradish peroxidase-conjugated antibody for
1 h. Immune complexes were detected by chemiluminescence
using Super Signal West Dura Extended Duration Substrate
(Thermo Scientific), and images were captured digitally by
use of the Fuji LAS3000 platform (Fujifilm, Tokyo, Japan) or
the Alpha Innotech FlourChem Q imaging platform (Kem-
En-Tec, Taastrup, Denmark).
2.6. Cell Death Detection Assay. Apoptotic cell death was
measured by the detection of DNA-histone complexes
released from the nucleus to the cytosol of cells by using
Cell Death Detection ELISAPLUS (Roche) as described by the
manufacturer. In brief, 0.075 × 106 INS-1 cells stably express-
ing JNK1, JNK2, JNK3, nonsense shRNA, or empty vector
were cultured 24 h prior to exposure to IL-1𝛽 (150 pg/mL)
or vehicle. After an additional 24 h, the culture medium
was removed and cells lysed in 200 𝜇L 1x lysis buffer for
30min at room temperature. The lysate was then centrifuged
for 10min at 200×g, incubated with anti-DNA peroxidase
and anti-histone-biotin, and added to streptavidin-coated
wells for 2 h at room temperature. Absorbance was measured
after addition of peroxidase substrate ABTS (2.2-azino-bis-3-
ethylbenzthiazoline-6-sulfonate) at 405 and 490 nm.
2.7. Statistical Analysis. All statistical analyses were per-
formed at raw data using GraphPad Prism (GraphPad Soft-
ware Inc., San Diego, CA, USA). Where the figures show
normalized data, the mean of the controls of the individual
experiment was set to 1 and the error bars show the standard
error calculated from the raw data. Statistical significance was
determined using one- or two-way ANOVA with post hoc
tests, or Student’s 𝑡-test as appropriate. 𝑃 values less than or
equal to 0.05 were considered statistically significant.
3. Results
3.1. JNK Isoform Expression and Activity in INS-1 Cell. The
JNK family of proteins consists of more than 10 isoforms.
In order to determine which isoforms are expressed in the
INS-1 cell model, we created rat-specific primers and probes
(Table 1), utilizing the human isoform-specific primer and
probe sequences determined by Dreskin et al. [34] andmodi-
fying them based upon a cross species homology comparison
between human andmouse, as the rat JNK isoform sequences
have not been published. Utilizing quantitative RT-PCR, we
found that the INS-1 cells expressed JNK1𝛼1, JNK1𝛽1, JNK2𝛼1,
JNK2𝛼2, JNK3𝛼1, and JNK3𝛼2. JNK1𝛼2 and JNK1𝛽2 were
expressed at very low levels and JNK2𝛽1 and JNK2𝛽2 were
not expressed in INS-1 cells (data not shown). We chose to
examine IL-1𝛽-induced regulation of the six isoforms with
the higher level of expression in the INS-1 cell line. We
exposed INS-1 cells to 150 pg/mL of IL-1𝛽 or vehicle for 2
to 24 h. We used 150 pg/mL IL-1𝛽 to induce apoptosis in the
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INS-1 cells as titration experiments showed that this was the
lowest concentration sufficient to induce maximal apoptosis
(data not shown). Utilizing RT-PCR, we found that JNK1𝛼1,
JNK1𝛽1, JNK2𝛼1, and JNK2𝛼2 were not regulated by IL-
1𝛽, whereas JNK3𝛼1 was significantly upregulated at 8 h and
JNK3𝛼2 was upregulated from 8 to 24 h (Figures 1(a)–1(f)).
Comparison of the data obtained with JNK isoform-specific
primers with data obtained with nonisoform-specific Taq-
man primers confirmed that JNK1 and JNK2 were not regu-
lated by IL-1𝛽, whereas JNK3 was upregulated from 6 to 12 h
(Supplementary Figures 1A–1C, in Supplementary Material
available online at http://dx.doi.org/10.1155/2016/1312705).
We next asked if IL-1𝛽 altered JNK protein expres-
sion in INS-1 cells. As there are no available commercial
JNK isoform-specific antibodies, we used JNK1, JNK2, or
JNK3 subtype specific antibodies. We exposed INS-1 cells
to 150 pg/mL IL-1𝛽 for 4 to 24 h to measure the expression
and regulation of the JNK subtype proteins by Western
blot analysis. The JNK1 subtype encompasses JNK1𝛼1 and
JNK1𝛽1 isoforms translating into 46 kDa and JNK1𝛼2 and
JNK1𝛽2 isoforms translating into 54 kDa isoform proteins,
respectively. We found that only JNK1 46 and 54 kDa isoform
proteins expressions were significantly regulated in that
they were decreased by IL-1𝛽 in a time-dependent man-
ner (Figure 2(a)). The JNK2 subtype includes JNK2𝛼1 and
JNK2𝛼2 translating into 46 kDa and 54 kDa isoformproteins,
respectively. The JNK2 antibody reacts only with the 54 kDa
isoform protein, compatible with JNK2𝛼2 being the predom-
inating JNK2 isoform expressed in INS-1 cells (unpublished
data).The JNK3 subtype specific antibody reacts onlywith the
54 kDa protein isoform corresponding to JNK3𝛼2; however,
JNK3𝛼1 that translates into a 46 kDa protein isoform and
JNK3𝛼2 are expressed at equally high levels in INS-1 cells
(unpublished data). However, the observed IL-1𝛽-induced
JNK3 mRNA expression did not translate into increased
JNK3 54 kDa isoform protein expression (Figure 2(a)). Of
note, detection of IL-1𝛽-regulated JNK3𝛼1 isoform protein
expression was not possible with this JNK3 subtype antibody.
Finally, we exposed INS-1 cells to 150 pg/mL IL-1𝛽 or
vehicle for 0.5 to 24 h to measure JNK phosphorylation as
a measure of JNK activity. JNK 46 and 54 kDa isoforms
were both significantly phosphorylated after 0.5 to 6 h of IL-
1𝛽 exposure, with maximum peak phosphorylation of the
isoforms after 0.5 to 1 h of IL-1𝛽 exposure (Figure 2(b)).
In summary, IL-1𝛽 increased JNK3𝛼1 and JNK3𝛼2mRNA
expression and decreased JNK1 subtype protein expression in
INS-1 cells. Furthermore, IL-1𝛽-induced JNK phosphoryla-
tion peaks after 0.5 to 6 h of stimulation.
3.2. JNK Knockdown INS-1 Cell Lines. To investigate the
differential roles of the JNK subtypes in IL-1𝛽-induced
cell death, we produced stable INS-1 knockdown cell lines
expressing shRNAs directed against JNK1, JNK2, or JNK3, as
well as nontarget (nonsense, NS) shRNA and empty vector
(EV) controls. The JNK knockdown cell lines were tested for
knockdown specificity and efficiency byWestern blot analysis
using JNK subtype specific antibodies (Figure 3(a)). We
achieved specific knockdown of the intended JNK subtypes
by approximately ∼80% JNK1, ∼75% JNK2, and ∼45% JNK3
knockdown compared to control NS (NS shRNA) INS-1 cells
(Figure 3(a)).
We next wished to measure early response JNK activity
in the stable JNK knockdown INS-1 cell lines to investigate
how knockdown of the individual JNK subtype affected total
phosphorylation status of the different JNK isoforms (46 or
54 kDa). We exposed the stable JNK knockdown INS-1 cells
to 150 pg/mL IL-1𝛽 or vehicle for 0.5 h (Figure 3(b)) as we
detected peak JNK phosphorylation at this time point in
nontransduced INS-1 cells (Figure 2(b)). Though the JNK
knockdown INS-1 cell lines showed specific JNK1, JNK2, or
JNK3 knockdown (Figure 3(b)), this did not affect the total
level of JNK (all JNK subtypes) (Figure 3(b)). Interestingly,
JNK1 knockdown (JNK1 shRNA) INS-1 cells showed signifi-
cantly reduced IL-1𝛽-induced phosphorylation of the 46 kDa
isoforms compared to control NS expressing INS-1 cells.
Phosphorylations of the 46 kDa isoforms in JNK2 knock-
down (JNK2 shRNA) and JNK3 knockdown (JNK3 shRNA)
INS-1 cells were not different compared to the control NS
INS-1 cells (Figure 3(b)). There were no differences in phos-
phorylation of the 54 kda JNK isoforms between 0.5 h IL-
1𝛽 exposed NS and JNK1, JNK2, or JNK3 knockdown INS-1
cell lines (Figure 3(b)). To summarize, only JNK1 knockdown
reduced early IL-1𝛽-mediated activity of the 46 kDa JNK
isoforms as determined by phosphorylation in INS-1 cells.
3.3. JNK1 Knockdown Attenuates IL-1𝛽-Induced Caspase 3
Activation and Apoptosis in INS-1 Cells. Next, to investigate
the functional impact of knockdown of the individual JNK
subtypes, we exposed the stable JNK knockdown and control
cell lines to 150 pg/mL of IL-1𝛽 or vehicle for 24 h, after which
apoptosis markers were measured by Elisa and Western
blotting. IL-1𝛽-induced apoptosis was observed in the control
NS and EV expressing INS-1 cells. In contrast, knockdown
of JNK1 prevented IL-1𝛽-induced apoptosis, measured as
decreased levels of cytoplasmic nucleosomes (Figure 4(a)).
JNK1 knockdown also attenuated IL-1𝛽-induced caspase 3
cleavage (Figure 4(b)). Interestingly, knockdown of JNK2 sig-
nificantly potentiated IL-1𝛽-induced apoptosis and caspase 3
activation, while JNK3 knockdowndid not significantly affect
IL-1𝛽-induced apoptosis or cleavage of caspase 3 compared to
NS cells.
Since the JNK members had differential effects on IL-1𝛽-
induced apoptosis, we next determined if there were unique
early response gene clusters regulated by each JNK member.
INS-1 cells stably expressing shRNAs directed against JNK1,
JNK2, JNK3, or NS were exposed to 150 pg/mL of IL-1𝛽
or vehicle for 45min. mRNA expression was analyzed by
microarray analysis. When we compared the normalized
gene expression profile of the 45min IL-1𝛽 exposed JNK1,
JNK2, or JNK3 knockdown INS-1 cells with the gene expres-
sion profile of 45min IL-1𝛽 exposed NS INS-1 cells, adjusted
for their IL-1𝛽 nonexposed control conditions, 74, 144, and
134 genes, respectively, were found to be differentially regu-
lated (Supplementary Tables 1–3).The JNK1 knockdown INS-
1 cell line gene expression pattern was significantly different
from that of JNK2 or JNK3 knockdown and NS INS-1 cells
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Figure 1: JNK isoform expression in INS-1 cell. INS-1 cells were exposed to 150 pg/mL IL-1𝛽 (square) or vehicle (circle) for 2 to 24 h. Relative
mRNA of the JNK isoforms was measured using quantitative RT-PCR and normalized to the average of 18S and hprt1. (a) Relative JNK1𝛼1
mRNA expression, (b) relative JNK1𝛽1 mRNA expression, (c) relative JNK2𝛼1 mRNA expression, (d) relative JNK2𝛽2 mRNA expression, (e)
relative JNK3𝛼1 mRNA expression, and (f) relative JNK3𝛼2 mRNA expression. Data are means ± SEM of 𝑛 = 4 independent experiments.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
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Figure 2: IL-1𝛽 reduces JNK1 but not JNK2 or JNK3 protein expression and increases P-JNK after 0.5 h of exposure in INS-1 cells. (a)
INS-1 cells were exposed to 150 pg/mL IL-1𝛽 or vehicle for 4 to 24 h. JNK subtypes protein expression, JNK1 (circle), JNK2 (square), and
JNK3 (triangle), were measured by immunoblotting and normalized to actin or tubulin. Data are shown as % IL-1𝛽-regulated JNK subtype
expression of their respective nonexposed controls. Data are shown as means of 𝑛 = 3–5 independent experiments ± SEM; ∗𝑃 < 0.05 versus
4 h time point. (b) INS-1 cells were exposed to 150 pg/mL IL-1𝛽 or vehicle for 0.5 to 24 h. INS-1 cells exposed for IL-1𝛽 for 12 h were lysed at
an earlier time point paralleled with the 12 h vehicle ctrl. P-JNK was measured by immunoblotting and normalized to T-JNK. Data are shown
as means of 𝑛 = 4 independent experiments ± SEM; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus vehicle (0 h). Representative gels are
shown.
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Figure 3: Phosphorylated JNK in individual JNK subtype knockdown INS-1 cell lines exposed to IL-1𝛽 for 0.5 h. INS-1 cells were transduced
with Lentivirus containing shRNA directed against JNK1, JNK2, or JNK3 and nonsense (NS) or empty vector (EV) controls. Cells stably
expressing the shRNA plasmids were selected with puromycin. (a) Stable INS-1 cell lines expressing shRNA for JNK1, JNK2, JNK3, nonsense
shRNA, or empty vector controls were cultured for 4 days, protein was isolated, and JNK1, JNK2, and JNK3 protein knockdown expression
was analyzed by immunoblotting. Data are shown as means ± SEM of 𝑛 = 3 independent experiments. Representative blots are shown. (b)
Stable INS-1 cell lines expressing shRNA for JNK1, JNK2, JNK3, nonsense shRNA, or empty vector were exposed to 150 pg/mL IL-1𝛽 (closed
bars) or vehicle (open bars) for 0.5 h. P-JNK was assessed with immunoblotting and normalized to T-JNK. Data were quantified in respect to
46 kDa and 54 kDa P-JNK/T-JNK. Data are shown asmeans ± SEM of 𝑛 = 3 independent experiments. Specific knockdowns of the individual
JNK subtypes, JNK1, JNK2, or JNK3, are shown with their respective actin. Blots were cut as indicated by the dotted black line. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus IL-1𝛽 exposed NS. Representative gels are shown.
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Figure 4: JNK1 knockdown attenuates IL-1𝛽-induced caspase 3 activation and apoptosis in INS-1 cells. Stable INS-1 cell lines expressing
shRNA for JNK1, JNK2, JNK3, nonsense shRNA, or empty vector controls were exposed to 150 pg/mL IL-1𝛽 (closed bars) or vehicle (open
bars) for 24 h. (a) Apoptosis was measured as the relative levels of cytoplasmic nucleosomes in INS-1 stable cell lines lysates using the Roche
Cell Death detection Elisa kit. Data are shown as means ± SEM of 𝑛 = 5 independent experiments. (b) Cleaved caspase 3 was assessed with
immunoblotting and normalized to actin. Data are shown as means ± SEM of 𝑛 = 4 independent experiments; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and
∗∗∗
𝑃 < 0.001, comparing caspase 3 activity in the presence with the activity in the absence of IL-1𝛽, unless otherwise indicated. Representative
gels are shown.
(Supplementary Figure 2). However, overall, there were no
significant clusters or pathway associations to cast light on
the potential pathways or early IL-1𝛽-induced mechanisms
underlying the unique actions of the JNK subtypes, and we
therefore decided to proceed with a candidate gene approach
to understand themechanisms of action of the JNK subtypes.
3.4. JNK1 Knockdown Attenuates the Increase of Myc mRNA
Expression by IL-1𝛽. We therefore next analyzed in the JNK
knockdown cells specific JNK-related signalling molecules
known to be regulated by the JNK proteins to determine if
the regulation of these genes by IL-1𝛽 is mediated specifically
by JNK1. INS-1 cells stably expressing shRNAdirected against
JNK1, JNK2, or JNK3, or theNS or EV controls, were exposed
to 150 pg/mL of IL-1𝛽 for 2, 6, and 12 h. IL-1𝛽 upregulated
Jun mRNA from 2 to 12 h, Trp53 mRNA at 6 and 12 h, Junb
mRNA from 2 to 12 h, Jund mRNA at 2 h, and Myc mRNA
at 12 h (Figures 5(a)–5(e)). These findings indicate that many
of the common JNK-related signalling proteins are regulated
by IL-1𝛽. Interestingly, there was a temporal difference in the
regulation of the mRNA transcripts, as Jun and Junb were
upregulated at all time points, whereas Myc was upregulated
only at 12 h and Jundwas upregulated significantly only at 2 h.
Knockdown of JNK1, JNK2, or JNK3 did not affect the
regulation of Trp53 or Junb mRNA expression by IL-1𝛽. This
indicates that these mRNA transcripts are not regulated by
JNK1, JNK2, or JNK3 specifically, either due to redundancy
in the actions of the JNKmembers or due to the fact that they
are not regulated by the JNK proteins in INS-1 cells. JNK1
knockdown increased basal Jun mRNA expression at 2 h
(Figure 5(a)) and attenuated the upregulation of Myc by IL-
1𝛽 at 12 h (Figure 5(e)), indicating that JNK1 may be involved
in the basal regulation of Jun and that it specifically mediates
the regulation of Myc mRNA expression by IL-1𝛽.
3.5. JNK1 Knockdown Attenuated the IL-1𝛽-Induced Increase
of Myc Protein Levels. Next, we wished to determine if IL-
1𝛽 regulates the levels of Myc protein and if JNK1 mediates
this regulation in response to IL-1𝛽. INS-1 cells were exposed
to 150 pg/mL of IL-1𝛽 or vehicle for 4 to 24 h, and protein
was analyzed by Western blot analysis. IL-1𝛽 increased the
total amount of Myc protein from 12 to 24 h (Figure 6(a)).
The increase in total Myc protein by IL-1𝛽 corresponded
to the timing of the upregulation of Myc mRNA by IL-1𝛽,
which we noted at 12 h (Figure 5(e)). Next, we exposed the
INS-1 cells stably expressing shRNA directed against JNK1,
JNK2, or JNK3, or the NS or EV controls to 150 pg/mL of
IL-1𝛽 or vehicle for 16 h. Knockdown of JNK1 prevented IL-
1𝛽 induction of total Myc protein expression (Figure 6(b)).
This indicates that JNK1 mediates IL-1𝛽 regulation of total
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Figure 5: JNK1 knockdown attenuates the regulation of Myc mRNA expression by IL-1𝛽. Stable INS-1 cell lines expressing shRNA for JNK1,
JNK2, JNK3, nonsense shRNA, or empty vector controls were exposed to 150 pg/mL IL-1𝛽 (closed bars) or vehicle (open bars) for 2, 6, and
12 h. Relative mRNA expression were measured using quantitative RT-PCR and normalized to the average of 18S and Hprt1. (a) Relative Jun
mRNA expression, (b) relative Trp53 mRNA expression, (c) relative Junb mRNA expression, (d) relative Jund mRNA expression, and (e)
relative Myc mRNA expression. Data are shown as means ± SEM of 3–5 independent experiments. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001,
comparing expression in the presence with expression in the absence of IL-1𝛽, unless otherwise indicated.
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Figure 6: JNK1 knockdown prevents the regulation of total Myc protein by IL-1𝛽. INS-1 cells were exposed to 150 pg/mL IL-1𝛽 (closed bars)
or vehicle (open bars) for 4 to 24 h. Protein was isolated and (a) total Myc protein levels were analyzed by immunoblotting. Total protein was
used as the loading control. Data are shown ± SEM of 𝑛 = 3-4 independent experiments. INS-1 cells stably expressing shRNA directed against
JNK1, JNK2, JNK3, or the nonsense or empty vector controls were exposed to 150 pg/mL IL-1𝛽 (black bars) or left unexposed (white bars) for
16 h. Protein was isolated, and (b) total Myc protein levels were analyzed by immunoblotting. Actin was used as the loading control. Data are
shown ± SEM of 𝑛 = 5 independent experiments. ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001 comparing Myc levels in the presence with Myc levels in the
absence of IL-1𝛽, unless otherwise indicated.
Myc protein levels. These results, taken together with the
data in Figure 5(e), indicate that JNK1mediates inflammatory
regulation ofMyc transcription and translation in INS-1 cells.
3.6. Myc Knockdown Attenuates IL-1𝛽-Induced Apoptosis in
INS-1 Cells. The Myc protein has been shown previously
to be involved in JNK-mediated apoptosis triggered by UV
irradiation or antineoplastic drugs [26, 35]. We therefore
wished to determine if Myc mediates IL-1𝛽-induced apop-
tosis in the INS-1 𝛽-cell model. INS-1 cells were transiently
transfected with either siRNA directed against Myc or a
control NS oligonucleotide sequence and then exposed to
150 pg/mL of IL-1𝛽 or vehicle for 24 h (Figure 7). Transfection
with siRNA directed against Myc decreased the total level
of Myc by ∼2.8-fold detected by Western blot analysis
(Figure 7(a)) and, interestingly, attenuated the IL-1𝛽-induced
caspase 3 activation by ∼3.2-fold (Figure 7(b)). In addition,
transfection of INS-1 cells with Myc siRNA attenuated IL-1𝛽-
induced apoptosis by ∼1.6-fold (Figure 7(c)). This indicates
that Myc may mediate IL-1𝛽-induced apoptosis in the INS-
1𝛽-cell line and, taken together with the previous results, that
the JNK1-Myc pathway is an important mediator of IL-1𝛽-
induced apoptosis.
4. Discussion
Few studies have investigated the differential roles of the
JNK subtypes in cellular apoptosis, or if there are specific
downstream signaling proteins utilized by a specific JNK
subtype to mediate its actions. It is known that IL-1𝛽 does
not induce apoptosis in most cells but the pancreatic 𝛽-
cells belong to the exceptions. Many studies have shown
that JNK plays an important role in cellular apoptosis and
specifically in cytokine and IL-1𝛽-induced 𝛽-cell apoptosis
[19] most using the nonspecific JNK inhibitor SP600125
[36]. We show here that JNK1𝛼1, JNK1𝛽1, JNK2𝛼1, JNK2𝛼2,
JNK3𝛼1, and JNK3𝛼2 isoforms are expressed in INS-1 cells
whereas only the JNK3 isoforms mRNA is regulated by
IL-1𝛽. When we analyzed JNK1, JNK2, and JNK3 subtype
protein expression, only JNK1 subtype was significantly
downregulated by IL-1𝛽 after 24 h of exposure. We believe
that this downregulation of JNK1 subtype is not mediated
by proteases after cell lysis since we use a broad protease
inhibitor cocktail in our lysis buffer. The reduced JNK1
subtype expression may though be a side effect of apoptosis
due to caspase 3-mediated cleavage; however, in other stress-
induced apoptotic cell lines, JNK protein expression is shown
to be caspase-independent [37, 38]. Gene expression profiling
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Figure 7: Myc knockdown attenuates IL-1𝛽-induced apoptosis in INS-1 cells. INS-1 cells were transfected with siRNA directed against Myc,
a scrambled siRNA control (NS) or vehicle (INS-1) for 16 h. Thereafter, cells were exposed to 150 pg/mL IL-1𝛽 (closed bars) or vehicle (open
bars) for 24 h. (a) Total Myc protein levels and (b) cleaved caspase 3 were analyzed by immunoblotting. Actin was used as the loading control.
Data are shown as means ± SEM of 3-4 independent experiments. Blots shown are representative. (c) Apoptosis was measured as relative
levels of cytoplasmic nucleosomes in lysates measured by the Roche Cell Death Elisa kit. Data are shown as means ± SEM of 3-4 independent
experiments. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus IL-1𝛽 exposed NS.
studies followed by functional characterization of candi-
date genes have demonstrated that the exposure of insulin-
producing cell lines, fluorescence-activated cell-sorted pri-
mary rodent 𝛽-cells, intact rodent islets, and human islets
to proinflammatory cytokines induces not only upregula-
tion of proapoptotic/downregulation of antiapoptotic genes,
but also a protective response including downregulation of
proapoptotic/upregulation of antiapoptotic genes, with a high
degree of concordance between the different model systems
[39, 40]. These findings suggest that inflammatory attack
on the pancreatic 𝛽-cell induces a race between deleterious
and protective responses, of which the deleterious pathways
eventually prevail [41]. We believe that the observed decrease
in JNK1 content following 16 h of exposure to IL-1𝛽 is a
late compensatory negative feedback mechanism serving to
suppress signaling via JNK1; however, this late suppression in
JNK1 content is insufficient to prevent apoptosis.
We selectively knocked down the three JNK subtypes
to understand their individual contributions. Knockdown of
JNK1 completely prevented IL-1𝛽-induced INS-1 cell apop-
tosis, while JNK2 knockdown potentiated cytokine-induced
INS-1 cell apoptosis. This is an interesting observation as
JNK2 has been shown to inhibit JNK1 signaling [42], and
thus knockdown of JNK2 may act to increase JNK1 activity.
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Knockdown of JNK3 did not significantly affect IL-1𝛽-
induced apoptosis compared toNS cells but an increase could
be observed, but not in levels of cleaved caspase 3. JNK3 has
been suggested as being protective against cytokine-induced
INS-1E cell death [15]. Both JNK1 and JNK2 knockdown
protected INS-1E cells against apoptosis by 40 and 60%,
respectively, in that study. We found complete protection
of apoptosis by JNK1 knockdown and found that JNK2
knockdown potentiated the effect of IL-1𝛽. Our study and
[15] differed in the following respects: we utilized INS-1
cells stably expressing shRNA, whereas Abdelli et al. used
transiently siRNA transfected INS-1E cells. However, the key
difference between these studies is the inflammatory stimulus
used. Abdelli et al. used a cytokine combination, containing
10 ng/mL IL-1𝛽, 25 ng/mL TNF-𝛼, and 150 ng/mL IFN-𝛾,
whilewe exposed INS-1 cells to only IL-1𝛽 at 150 pg/mL. TNF-
𝛼 receptor is a death-domain containing receptor and acti-
vates caspase 8 directly. The TNFR also signals through JNK
and NF𝜅B, as does the IL-1 receptor. IFN-𝛾 signals through
the JAK-STAT pathway. Thus, using a cytokine combination,
confounding pathways and downstream signaling molecules
are activated compared to testing IL-1𝛽 alone. However, as
we only achieved ∼50% knockdown of JNK3 in this study,
new studies with more efficient JNK3 knockdown might
acknowledge JNK3 as a protective protein.
We also investigated early IL-1𝛽-induced JNK phospho-
rylation as a surrogate for JNKactivity in the JNKknockdown
INS-1 cells. Here, we only observed significant reduction of
phosphorylation of the 46 kDa isoform in 0.5 h IL-1𝛽 exposed
JNK1 knockdown INS-1 cells when compared to NS INS-1
cells.This was not surprising to us as themajor JNK1 isoforms
expressed in INS-1 cells translate into 46 kDa proteins and as
we achieved a high JNK1 knockdown efficiency in the JNK1
knockdown INS-1 cell line. Despite high specific knockdown
of the individual JNK subtypes in the shRNA expressing
INS-1 cell lines, we did not see any changes in total levels
of JNK. The total JNK antibody recognizes all three JNK
subtypes and therefore a reduction in only one subtype is
unlikely to affect the total amount of JNK. The reduced
46 kDa phosphorylation might explain the decreased IL-
1𝛽-induced apoptosis in JNK1 knockdown INS-1 cells as
inhibition of total JNK activity decreases intracellular JNK
signalling and improves rodent 𝛽-cell survival in vitro in
response to cytokines [5, 18, 19, 43]. We did not observe
altered 54 kDa isoform phosphorylation between 0.5 h IL-1𝛽
exposed NS and JNK1, JNK2, or JNK3 perhaps indicating
that IL-1𝛽-induced phosphorylation in the individual JNK
knockdown subtype INS-1 cells is covered by the remaining
JNK isoforms.
There aremany potential downstream targets of JNK1 that
activate apoptosis, such as the mitochondrial stress pathway
and caspase activation, but there are few studies analyzing if
there are specific signaling proteins or transcription factors
that are uniquely regulated by each JNK subtype. We per-
formedmicroarray mRNA expression profiling to investigate
the genes regulated by the JNK subtypes. There were no
differences in basal gene expression levels in JNK1, JNK2,
or JNK3 shRNA expressing INS-1 cells when compared to
NS shRNA expressing INS-1 cells, indicating that individual
JNK subtype knockdown does not initiate differential basal
gene regulation. Exposure of the cells to IL-1𝛽 for 45min
initiated differential gene regulation; however, no significant
clusters were identified. This indicates that the JNK subtypes
might mediate their major differential effect by modulating
activity of proteins rather than affecting early IL-1𝛽-induced
gene transcription in 𝛽-cells. Using a transcription factor
candidate gene expression analysis, we found that Myc was
specifically regulated by JNK1 after 12 h of IL-1𝛽 exposure.
We found that Myc mRNA and total protein levels were
specifically downregulated in JNK1 knockdown INS-1 cells
and that knockdown of Myc decreased IL-1𝛽-induced apop-
tosis and cleaved caspase 3. In addition to activating Myc
expression, JNK proteins are known to increase the stability
of the Myc protein [44] that normally has a short half-life
of approximately 30 minutes. Our data also suggests that
JNK1 increases the stability of total Myc, as Myc protein
levels were increased in wild-type INS-1 cells by IL-1𝛽
from 16 h to 24 h; additionally, we found that Myc mRNA
expression was increased at 12 h. This increase could be due
to an increased stability of the mRNA transcript, as opposed
to transcriptional activation, given that there is a delayed
increase in Myc mRNA expression relative to other JNK-
regulated genes, such as Jun, Junb, and Jund, which were all
increased at 2 h.
Myc is involved in mediating numerous cellular func-
tions, including cell proliferation, growth, differentiation, and
apoptosis [45].There is much debate as to howMyc regulates
these opposing cellular processes, but it seems to be through
a complex and intricate balance between Myc and its protein
interaction partner MAX, as well as other signaling pathways
[45]. There are also numerous pathways through which Myc
can promote cellular death. Myc induces the expression
of the tumor suppressor protein cyclin-dependent kinase
inhibitor 2A, which stabilizes p53, an important regulator
of apoptosis, by sequestering the E3 ubiquitin-protein ligase,
mouse double minute 2 homolog, in turn degrading p53
[46]. Myc also induces the proapoptotic BH3-only protein,
Bim, and blocks the expression of the antiapoptotic proteins
Bcl-2 and Bcl-xl. Myc has been shown to promote intrinsic
cell death by destabilizing via the Bax protein [47]. Thus,
Myc knockdown in cisplatin-induced apoptosis in A549
human lung carcinoma cells blocked cytochrome C release
and prevented Bax oligomerization [48]. Another potential
death promotingmechanism is through the p53-p21 pathway.
Myc binds to the cell cycle gene p21CIP1 promoter, thereby
preventing p53-induced transcription [49]. p53 induction of
p21CIP1 drives the cell into senescence, and blocking p21
upregulation redirects the actions of p53 to activate apoptotic
pathways [49]. p53 was significantly upregulated in INS-1
cells following IL-1𝛽 treatment; however, when we analyzed
p21CIP1mRNAexpression in the INS-1 cells stably expressing
JNK1 shRNA, we did not observe a decrease in expression,
and thus we do not favor this mechanism of action.
In nonstressed islets, Myc expression is low [50] and 𝛽-
cell specific Myc overexpression markedly increases 𝛽-cell
apoptosis [51]. Here, we suggest that Myc is a key mediator
of IL-1𝛽-induced apoptosis in the INS-1 cell model. We
additionally propose that JNK1 specifically regulates Myc,
14 Journal of Diabetes Research
implicatingMyc as a potential downstream relay of the apop-
totic effect of JNK1. Further experiments are likewise required
to verify the direct involvement of Myc in mediating the
apoptotic actions of JNK1, such as overexpression of JNK1
combined with Myc knockdown.
5. Conclusion
In summary, this study suggests that JNK1 is a key mediator
of IL-1𝛽-induced INS-1 cell apoptosis, that the transcription
factor Myc is regulated specifically by JNK1, and that Myc
may mediate the apoptotic actions of JNK1. Future studies
are required to investigate if the JNK1-Myc pathway is
involved in cytokine-induced apoptosis in other cell types
to determine if this is a pancreatic 𝛽-cell specific effect or
a more general cellular effect. We propose that the JNK1-
Myc pathway may be a target for protecting pancreatic 𝛽-
cells from inflammatory stress, and thus a potential treatment
target in diabetes.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This study is supported by Novo Nordisk and the Novo
Nordisk Foundation and the PhD Program for Molecular
Metabolism.The authors are thankful to FieHillesø for expert
technical assistance.
References
[1] T. Mandrup-Poulsen, L. Pickersgill, and M. Y. Donath, “Block-
ade of interleukin 1 in type 1 diabetes mellitus,” Nature Reviews
Endocrinology, vol. 6, no. 3, pp. 158–166, 2010.
[2] C. A. Dinarello, M. Y. Donath, and T. Mandrup-Poulsen,
“Role of IL-1beta in type 2 diabetes,” Current Opinion in
Endocrinology, Diabetes and Obesity, vol. 17, no. 4, pp. 314–321,
2010.
[3] C. A. Dinarello, “Interleukin-1 in the pathogenesis and treat-
ment of inflammatory diseases,” Blood, vol. 117, no. 14, pp. 3720–
3732, 2011.
[4] L. G. Grunnet, R. Aikin, M. F. Tonnesen et al., “Proinflamma-
tory cytokines activate the intrinsic apoptotic pathway in 𝛽-
cells,” Diabetes, vol. 58, no. 8, pp. 1807–1815, 2009.
[5] A. Ammendrup, A. Maillard, K. Nielsen et al., “The c-Jun
amino-terminal kinase pathway is preferentially activated by
interleukin-1 and controls apoptosis in differentiating pancre-
atic beta-cells,” Diabetes, vol. 49, no. 9, pp. 1468–1476, 2000.
[6] E. N. Gurzov, F. Ortis, D. A. Cunha et al., “Signaling by IL-
1𝛽+IFN-𝛾 and ER stress converge on DP5/Hrk activation: a
novel mechanism for pancreatic 𝛽-cell apoptosis,” Cell Death &
Differentiation, vol. 16, no. 11, pp. 1539–1550, 2009.
[7] M. Y. Donath, J. Størling, L. A. Berchtold, N. Billestrup, and T.
Mandrup-Poulsen, “Cytokines and𝛽-cell biology: fromconcept
to clinical translation,” Endocrine Reviews, vol. 29, no. 3, pp.
334–350, 2008.
[8] M. Hibi, A. Lin, T. Smeal, A.Minden, andM. Karin, “Identifica-
tion of an oncoprotein- and UV-responsive protein kinase that
binds and potentiates the c-Jun activation domain,” Genes and
Development, vol. 7, no. 11, pp. 2135–2148, 1993.
[9] R. J. Davis, “Signal transduction by the JNK group of MAP
kinases,” Cell, vol. 103, no. 2, pp. 239–252, 2000.
[10] T. Kallunki, B. Su, I. Tsigelny et al., “JNK2 contains a specificity-
determining region responsible for efficient c-Jun binding and
phosphorylation,” Genes and Development, vol. 8, no. 24, pp.
2996–3007, 1994.
[11] B. De´rijard, M. Hibi, I.-H. Wu et al., “JNK1: a protein kinase
stimulated by UV light and Ha-Ras that binds and phosphory-
lates the c-Jun activation domain,” Cell, vol. 76, no. 6, pp. 1025–
1037, 1994.
[12] A. M. Bode and Z. Dong, “The functional contrariety of JNK,”
Molecular Carcinogenesis, vol. 46, no. 8, pp. 591–598, 2007.
[13] S. Gupta, T. Barrett, A. J.Whitmarsh et al., “Selective interaction
of JNK protein kinase isoforms with transcription factors,”The
EMBO Journal, vol. 15, no. 11, pp. 2760–2770, 1996.
[14] C.-Y. Kuan, D. D. Yang, D. R. Samanta Roy, R. J. Davis, P.
Rakic, and R. A. Flavell, “The Jnk1 and Jnk2 protein kinases
are required for regional specific apoptosis during early brain
development,” Neuron, vol. 22, no. 4, pp. 667–676, 1999.
[15] S. Abdelli, J. Puyal, C. Bielmann et al., “JNK3 is abundant in
insulin-secreting cells and protects against cytokine-induced
apoptosis,” Diabetologia, vol. 52, no. 9, pp. 1871–1880, 2009.
[16] C. Tournier, P. Hess, D. D. Yang et al., “Requirement of JNK for
stress-induced activation of the cytochrome c-mediated death
pathway,” Science, vol. 288, no. 5467, pp. 870–874, 2000.
[17] D. D. Yang, C.-Y. Kuan, A. J. Whitmarsh et al., “Absence of
excitotoxicity-induced apoptosis in the hippocampus of mice
lacking the Jnk3 gene,” Nature, vol. 389, no. 6653, pp. 865–870,
1997.
[18] C. Bonny, A. Oberson, S. Negri, C. Sauser, and D. F. Schorderet,
“Cell-permeable peptide inhibitors of JNK: novel blockers of 𝛽-
cell death,” Diabetes, vol. 50, no. 1, pp. 77–82, 2001.
[19] S. Abdelli, A. Abderrahmani, B. J. Hering, J. S. Beckmann,
and C. Bonny, “The c-Jun N-terminal kinase JNK participates
in cytokine- and isolation stress-induced rat pancreatic islet
apoptosis,” Diabetologia, vol. 50, no. 8, pp. 1660–1669, 2007.
[20] G. Spigolon, C. Veronesi, C. Bonny, and A. Vercelli, “c-Jun
N-terminal kinase signaling pathway in excitotoxic cell death
following kainic acid-induced status epilepticus,” European
Journal of Neuroscience, vol. 31, no. 7, pp. 1261–1272, 2010.
[21] Y. Zhao, G. Spigolon, C. Bonny, J. Culman, A. Vercelli, and
T. Herdegen, “The JNK inhibitor D-JNKI-1 blocks apoptotic
JNK signaling in brain mitochondria,” Molecular and Cellular
Neuroscience, vol. 49, no. 3, pp. 300–310, 2012.
[22] D. A. Cunha, P. Hekerman, L. Ladrie`re et al., “Initiation and
execution of lipotoxic ER stress in pancreatic 𝛽-cells,” Journal
of Cell Science, vol. 121, no. 14, pp. 2308–2318, 2008.
[23] P.Wang, Y. Xiong, C.Ma, T. Shi, and D.Ma, “Molecular cloning
and characterization of novel human JNK2 (MAPK9) transcript
variants that showdifferent stimulation activities onAP-1,”BMB
Reports, vol. 43, no. 11, pp. 738–743, 2010.
[24] R. K. Barr and M. A. Bogoyevitch, “The c-Jun N-terminal
protein kinase family of mitogen-activated protein kinases
(JNK MAPKs),” International Journal of Biochemistry and Cell
Biology, vol. 33, no. 11, pp. 1047–1063, 2001.
[25] M. A. Bogoyevitch, “The isoform-specific functions of the c-
Jun N-terminal kinases (JNKs): differences revealed by gene
targeting,” BioEssays, vol. 28, no. 9, pp. 923–934, 2006.
Journal of Diabetes Research 15
[26] K. Noguchi, C. Kitanaka, H. Yamana, A. Kokubu, T. Mochizuki,
and Y. Kuchino, “Regulation of c-Myc through phosphorylation
at Ser-62 and Ser-71 by c-Jun N-terminal kinase,”The Journal of
Biological Chemistry, vol. 274, no. 46, pp. 32580–32587, 1999.
[27] X. Deng, L. Xiao, W. Lang, F. Gao, P. Ruvolo, and W. S. May
Jr., “Novel role for JNK as a stress-activated Bcl2 kinase,” The
Journal of Biological Chemistry, vol. 276, no. 26, pp. 23681–
23688, 2001.
[28] S. Abdelli and C. Bonny, “JNK3 maintains expression of the
insulin receptor substrate 2 (IRS2) in insulin-secreting cells:
functional consequences for insulin signaling,” PLoS ONE, vol.
7, no. 5, Article ID e35997, 2012.
[29] M. Asfari, D. Janjic, P. Meda, G. Li, P. A. Halban, and C.
B. Wollheim, “Establishment of 2-mercaptoethanol-dependent
differentiated insulin-secreting cell lines,” Endocrinology, vol.
130, no. 1, pp. 167–178, 1992.
[30] M. Prause, D. P. Christensen, N. Billestrup, and T. Mandrup-
Poulsen, “JNK1 protects against glucolipotoxicity-mediated
beta-cell apoptosis,” PLoS ONE, vol. 9, no. 1, Article ID e87067,
2014.
[31] G. Rustici, N. Kolesnikov, M. Brandizi et al., “ArrayExpress
update—trends in database growth and links to data analysis
tools,” Nucleic Acids Research, vol. 41, no. 1, pp. D987–D990,
2013.
[32] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic
and integrative analysis of large gene lists using DAVID bioin-
formatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57,
2008.
[33] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Bioin-
formatics enrichment tools: paths toward the comprehensive
functional analysis of large gene lists,” Nucleic Acids Research,
vol. 37, no. 1, pp. 1–13, 2009.
[34] S. C. Dreskin, G. W. Thomas, S. N. Dale, and L. E. Heasley,
“Isoforms of jun kinase are differentially expressed and acti-
vated in human monocyte/macrophage (THP-1) cells1,” Journal
of Immunology, vol. 166, no. 9, pp. 5646–5653, 2001.
[35] K. Noguchi, H. Yamana, C. Kitanaka, T. Mochizuki, A. Kokubu,
and Y. Kuchino, “Differential role of the JNK and p38 MAPK
pathway in c-myc- and s-myc-mediated apoptosis,” Biochemical
and Biophysical Research Communications, vol. 267, no. 1, pp.
221–227, 2000.
[36] J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein
kinase inhibitors: a further update,” Biochemical Journal, vol.
408, no. 3, pp. 297–315, 2007.
[37] C. Widmann, S. Gibson, and G. L. Johnson, “Caspase-de-
pendent cleavage of signaling proteins during apoptosis. A turn-
off mechanism for anti-apoptotic signals,” Journal of Biological
Chemistry, vol. 273, no. 12, pp. 7141–7147, 1998.
[38] A. Poehlmann, K. Reissig, P. Scho¨nfeld et al., “Repeated H
2
O
2
exposure drives cell cycle progression in an in vitro model of
ulcerative colitis,” Journal of Cellular and Molecular Medicine,
vol. 17, no. 12, pp. 1619–1631, 2013.
[39] A. K. Cardozo, M. Kruhøffer, R. Leeman, T. Ørntoft, and
D. L. Eizirik, “Identification of novel cytokine-induced genes
in pancreatic 𝛽-cells by high-density oligonucleotide arrays,”
Diabetes, vol. 50, no. 5, pp. 909–920, 2001.
[40] B. Kutlu, A. K. Cardozo, M. I. Darville et al., “Discovery of
gene networks regulating cytokine-induced dysfunction and
apoptosis in insulin-producing INS-1 cells,”Diabetes, vol. 52, no.
11, pp. 2701–2719, 2003.
[41] D. L. Eizirik and T. Mandrup-Poulsen, “A choice of death—the
signal-transduction of immune-mediated beta-cell apoptosis,”
Diabetologia, vol. 44, no. 12, pp. 2115–2133, 2001.
[42] J. Liu, Y. Minemoto, and A. Lin, “c-Jun N-terminal protein
kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis
factor alpha-induced c-Jun kinase activation and apoptosis,”
Molecular and Cellular Biology, vol. 24, no. 24, pp. 10844–10856,
2004.
[43] C. Bonny,A.Oberson,M. Steinmann,D. F. Schorderet, P.Nicod,
and G. Waeber, “IB1 reduces cytokine-induced apoptosis of
insulin-secreting cells,” Journal of Biological Chemistry, vol. 275,
no. 22, pp. 16466–16472, 2000.
[44] K. Noguchi, A. Kokubu, C. Kitanaka, H. Ichijo, and Y. Kuchino,
“ASK1-signaling promotes c-Myc protein stability during apop-
tosis,” Biochemical and Biophysical Research Communications,
vol. 281, no. 5, pp. 1313–1320, 2001.
[45] S. Pelengaris, M. Khan, and G. Evan, “c-MYC: more than just a
matter of life and death,” Nature Reviews Cancer, vol. 2, no. 10,
pp. 764–776, 2002.
[46] C. J. Sherr, “Divorcing ARF and p53: an unsettled case,” Nature
Reviews Cancer, vol. 6, no. 9, pp. 663–673, 2006.
[47] P. Juin, A. Hunt, T. Littlewood et al., “c-Myc functionally coop-
erates with Bax to induce apoptosis,” Molecular and Cellular
Biology, vol. 22, no. 17, pp. 6158–6169, 2002.
[48] X. Cao, R. L. Bennett, and W. S. May, “c-Myc and caspase-2
are involved in activating bax during cytotoxic drug-induced
apoptosis,” Journal of Biological Chemistry, vol. 283, no. 21, pp.
14490–14496, 2008.
[49] J. Seoane, H.-V. Le, and J. Massague´, “Myc suppression of
the 𝑝21𝐶𝑖𝑝1 Cdk inhibitor influences the outcome of the p53
response to DNA damage,” Nature, vol. 419, no. 6908, pp. 729–
734, 2002.
[50] J.-C. Jonas, D. R. Laybutt, G. M. Steil et al., “High glucose stim-
ulates early response gene c-Myc expression in rat pancreatic
beta cells,”The Journal of Biological Chemistry, vol. 276, no. 38,
pp. 35375–35381, 2001.
[51] D. R. Laybutt, G. C. Weir, H. Kaneto et al., “Overexpression
of c-Myc in 𝛽-cells of transgenic mice causes proliferation
and apoptosis, downregulation of insulin gene expression, and
diabetes,” Diabetes, vol. 51, no. 6, pp. 1793–1804, 2002.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
